Sydney Lupkin
Sydney Lupkin is the pharmaceuticals correspondent for NPR.
She was most recently a correspondent at Kaiser Health News, where she covered drug prices and specialized in data reporting for its enterprise team. She's reported on how , how and . She's also tracked pharmaceutical dollars to and . Her work has won the National Press Club's Joan M. Friedenberg Online Journalism Award, the National Institute for Health Care Management's Digital Media Award and a health reporting award from the Society for Advancing Business Editing and Writing.
Lupkin graduated from Boston University. She's also worked for ABC News, VICE News, MedPage Today and The Bay Citizen. Her internship and part-time work includes stints at ProPublica, The Boston Globe, The Boston Herald, The New England Center for Investigative Reporting and WCVB.
-
Though the FDA narrowed criteria for the shots, many people still want them, to avoid illness and protect vulnerable family members. Some are turned down at the pharmacy or have to jump through hoops. -
As coverage of this year's crop of COVID boosters hangs in the balance under Robert F. Kennedy Jr.'s leadership, what is the vaccine supply situation this year?
-
President Trump signed a memo on Tuesday directing the FDA to crack down on direct-to-consumer drug advertisements. But there are limits to what any administration can do.
-
For women with hair loss, there are more treatment options than ever before 鈥� and more ways to access them, as anyone scrolling social media has likely seen firsthand. But it can be confusing.
-
Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the name-brand medicine. The company says it trying to stop them. -
President Trump is pushing drugmakers to move production back to the United States. He's upping the ante with tariffs to encourage the shift. But would tariffs on imported drugs be enough?
-
Journavx is the first truly new painkiller approved by the Food and Drug Administration in more than 20 years. But the drug is expensive, and many people can't get it yet. -
The first new non-opioid for severe acute pain has been on the market for a few months. But it's a lot more expensive than opioids, and many people can't get it because of spotty insurance coverage.
-
Advisers to the Centers for Disease Control and Prevention recommended against flu shots containing the ingredient thimerosal. Why is the additive, safely used since the 1930s, being questioned again? -
Thimerosal has been a target of groups that question vaccine safety. What vaccines still contain the mercury compound, and what would happen if the recommendations against its use become official?
